PRME — Prime Medicine, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1894562 ·
Last close
$3.84
Market Cap
$854.20M
52W High
$5.91
52W Low
$2.67
ADV30
5,926,492
Next earnings
2026-11-12
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 4,213,000 — -39,926,000 -39,043,000 213,855,000 54,886,000 205,418,000
Jun 2026 1,154,000 — -43,285,000 -42,109,000 249,040,000 47,451,000 209,231,000
Mar 2026 856,000 — -50,654,000 -49,122,000 294,730,000 64,106,000 218,030,000
Dec 2025 838,000 — -48,608,000 -46,079,000 342,733,000 63,032,000 221,865,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-156,051,000
Investing CF
$3,629,000
Financing CF
$146,069,000
CapEx
$-797,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$979,585,000
Inventory
—
Receivables
$120,000
ST Investments
$71,391,000
EBIT TTM
$-196,520,000
Pretax Income TTM
$-187,892,000
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,061,000
EBITDA
$-175,196,992
Free Cash Flow
$-74,296,624
Enterprise Value
$811,240,640
Total Cash
$61,157,000
Total Debt
$110,421,000
Shares Out
222,448,284
Trailing EPS
$-0.97
Book Value
$0.05
ROE
-207.2%
ROA
-38.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,632,000 -208,350,000 -201,142,000 342,733,000 221,865,000 120,868,000 -162,564,000
Dec 2024 2,983,000 -202,467,000 -195,882,000 297,508,000 144,359,000 153,149,000 -122,865,000
Dec 2023 0 -191,292,000 -198,133,000 193,851,000 60,780,000 133,071,000 -165,412,000
Dec 2022 0 -116,544,000 -121,821,000 360,314,000 44,044,000 316,270,000 -131,827,000

TTM Snapshot

Revenues TTM
$3,872,000
NetIncome TTM
$-187,892,000
OpCashFlow TTM
—
Assets (Latest)
$249,040,000
Forward EPS
$-0.83

Max Pain — expiry 2027-01-15

max pain strike: $4.00 · spot: $3.82 · call oi: 9,605 · put oi: 3,222
Expected Move to 2027-01-15: ±$1.25 (32.72%) — implied range $2.57 – $5.07 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BBTX Bambusa Therapeutics, Inc. $832.91M $16.35 —
MGTX MeiraGTx Holdings plc $826.80M $8.46 —
ODTX Odyssey Therapeutics, Inc. $931.07M $19.37 —
GLUE Monte Rosa Therapeutics, Inc. $775.03M $9.07 —
IMTX Immatics N.V. $957.50M $6.29 —

News headlines (Yahoo Finance, 1h cache)

Prime Medicine's Financing Removes Major Overhang With Major Upside Opportunities in 2027, Oppenheimer Says
2026-11-13 17:05 · Yahoo
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 21:25 · Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
2026-11-12 21:15 · Yahoo
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 21:01 · Yahoo
Prime Medicine Announces Pricing of Public Offering of Common Stock
2026-11-11 02:40 · Yahoo
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
2026-11-10 21:05 · Yahoo
Prime Medicine to Present at Jefferies Global Healthcare Conference
2026-11-09 13:00 · Yahoo
Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?
2026-10-29 06:41 · Yahoo
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
2026-10-28 19:34 · Yahoo
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
2026-10-12 15:24 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.